Congenital Hereditary And Neonatal Diseases clinical trials

Explore recruiting congenital hereditary and neonatal diseases clinical trials.

Recruiting congenital hereditary and neonatal diseases studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Congenital Hereditary And Neonatal Diseases trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An Open Label Study to Determine the Long Term Safety, Tolerability and Biological Activity of SAR422459 in Patients with Stargardt’s Macular Degeneration

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Neonatal hypoxic ischemic encephalopathy : safety and feasibility study of a curative treatment with autologous cord blood stem cells (NEOSTEM)

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Study to Evaluate the Pharmacokinetics of Afamelanotide in Patients with Erythropoietic Protoporphyria (EPP).

Belgium, Netherlands

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Open-label safety study in adults and adolescents with haemophilia A with and without FVIII inhibitors switching directly from emicizumab prophylaxis to NNC0365-3769 (Mim8) prophylaxis.

Belgium, Spain, France, Austria, Italy, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Long-Term Extension Trial Investigating the Safety and Efficacy of GTX-102 in Patients with Angelman Syndrome

France, Spain, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease

France, Italy, Netherlands, Belgium, Greece, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

Congenital Hereditary And Neonatal Diseases trials by city

Congenital Hereditary And Neonatal Diseases in Toronto Congenital Hereditary And Neonatal Diseases in Vancouver Congenital Hereditary And Neonatal Diseases in Montreal Congenital Hereditary And Neonatal Diseases in Calgary Congenital Hereditary And Neonatal Diseases in Edmonton Congenital Hereditary And Neonatal Diseases in Ottawa Congenital Hereditary And Neonatal Diseases in Winnipeg Congenital Hereditary And Neonatal Diseases in Quebec City Congenital Hereditary And Neonatal Diseases in Hamilton Congenital Hereditary And Neonatal Diseases in Kitchener Congenital Hereditary And Neonatal Diseases in London Congenital Hereditary And Neonatal Diseases in Halifax Congenital Hereditary And Neonatal Diseases in New York Congenital Hereditary And Neonatal Diseases in Los Angeles Congenital Hereditary And Neonatal Diseases in Chicago Congenital Hereditary And Neonatal Diseases in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease